Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
- Registration Number
- NCT04806243
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Brief Summary
To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.
- Detailed Description
Currently, there is little experience in the application of targeted drugs combined with immunotherapy. Through this study, we hope to explore the optimal population for the use of carelizumab combined with regorafenib in the second-line treatment of hepatocellular carcinoma (HCC), as well as the efficacy and safety.
This research is a single-center trials phase II second-line, single arm, explore the clinical outcome of treatment.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 69
- Not convenient to disclose
- Not convenient to disclose
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Carelizumab Combined With Regorafenib arm Regorafenib Pill&Camrelizumab -
- Primary Outcome Measures
Name Time Method os（overall survival） 21 days overall survival
- Secondary Outcome Measures
Name Time Method ORR（Overall Response Rate） 21 days Overall Response Rate
DCR（disease control rate） 21 days disease control rate
DoR 21 days Duration of Response
PFS（progression-free survival） 21 days progression-free survival
TTP（Time-To-Progression） 21 days Time-To-Progression
Trial Locations
- Locations (1)
NanFang Hospital of Southern Medical University
🇨🇳Guangzhou, Guangdong, China